


# Supplementary Materials


## Supplementary Figures



**Figure S1. CPT1C knockdown triggers cellular senescence in MDA-MB-231 cells.**

**A** Relative *CPT1C* mRNA expression was measured post-transfection with siRNA *CPT1C* in MDA-MB-231 cells, n=4. **B** CPT1C protein expression was detected in MDA-MB-231 cells after transfection


with siRNA *CPTIC*. Left panel of B shows images and right panel of B shows densitometric analysis of western blot, n=3. **C** The number of MDA-MB-231 cells transfected with siRNA *CPTIC* was decreased in replicating DNA synthesis measured by BrdU incorporation, n=5. **D** The colony formation of MDA-MB-231 cells was inhibited after transfection with siRNA *CPTIC* in a concentration-dependent manner. **E** Representative images of SA- $\beta$ -gal activity of MDA-MB-231 cells transfected with siRNA *CPTIC* or siControl. **F** MDA-MB-231 cells transfected with siRNA *CPTIC* showed higher SA- $\beta$ -gal activity, n=5. Data are represented as mean  $\pm$  S.E.M, \* $p < 0.05$ , \*\* $p < 0.01$ , # $p < 0.0001$  versus the siControl group.



**Figure S2. Stearate confers to cellular senescence in PANC-1 cells.**

**A** Relative *CPT1C* mRNA expression in PANC-1 cells transfected with siRNA *CPT1C*, n=3-4. **B** *CPT1C* protein level in PANC-1 cells after transfection with siRNA *CPT1C*. (Left panel of **B**) western


blot images and (right panel of **B**) densitometric analysis, n=3-4. **C** Cellular viability profile plots in PANC-1 cells cultured with a series of concentrations of BSA conjugated-stearate or BSA control, n=3. **D** BSA conjugated-stearate induced PANC-1 cells lower proliferation, n=4-5. **E** BSA conjugated-stearate reduced the colony formation ability of PANC-1 cells transfected with siRNA *CPTIC* or siControl. **F** Representative images of SA- $\beta$ -gal activity in PANC-1 cells cultured with BSA conjugated-stearate or BSA control. **G** BSA conjugated-stearate increased SA- $\beta$ -gal activity of PANC-1 cells transfected with siRNA *CPTIC* or siControl, n=5. Data are represented as mean  $\pm$  S.E.M, \*\* $p < 0.01$ , \*\*\* $p < 0.001$  versus the siControl-BSA group, # $p < 0.05$ , ### $p < 0.001$  versus the siRNA *CPTIC*-BSA group.



**Figure S3. Oleate causes an increase in proliferation and reverses senescent phenotype induced by silencing CPT1C in PANC-1 cells.**

**A** Cellular viability profile plots in PANC-1 cells cultured with a series of concentrations of BSA conjugated-oleate, n=3. **B** BSA conjugated-oleate induced PANC-1 cells higher proliferation, n=3-4. **C** BSA conjugated-oleate up-regulated the colony formation ability of PANC-1 cells transfected with

siRNA *CPTIC* or siControl. **D** Representative images of SA- $\beta$ -gal activity in PANC-1 cells cultured with BSA conjugated-oleate or BSA control. **E** BSA conjugated-oleate decreased SA- $\beta$ -gal activity of PANC-1 cells transfected with siRNA *CPTIC*, n=5. Data are represented as mean  $\pm$  S.E.M, \* $p$  < 0.05, \*\* $p$  < 0.01, \*\*\* $p$  < 0.001 versus the siControl-BSA group, # $p$  < 0.05, ### $p$  < 0.001 versus the siRNA *CPTIC*-BSA group.



**Figure S4. SCD-1 inhibitor A939572 confers to cellular senescence in PANC-1 cells.**

**A** Cellular viability profile plot in PANC-1 cells cultured with a series of concentrations of SCD-1 inhibitor A939572, n=3. **B** A939572 induced PANC-1 cells lower proliferation, n=3-4. **C** A939572 down-regulated the colony formation ability of PANC-1 cells transfected with siRNA *CPT1C* or

siControl. **D** Representative images of SA- $\beta$ -gal activity in PANC-1 cells cultured with A939572. **E** A939572 increased SA- $\beta$ -gal activity of PANC-1 cells transfected with siRNA *CPTIC* or siControl, n=6. Data are represented as mean  $\pm$  S.E.M, \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$  versus the siControl-DMSO group, #  $p < 0.05$ , ##  $p < 0.01$  versus the siRNA *CPTIC*-DMSO group.

## Supplementary Tables

**Table S1. Sequences of RNAi assays.**

RNAi Name	Species Specificity	Sequences
siRNA <i>CPTIC</i> -1	Human	5'-GCCAUGAUCGCGUGGUUUGA dTdT-3'
siRNA <i>CPTIC</i> -2	Human	5'-CGGCCAUGACUCGCUUAUU dTdT-3'
siRNA <i>CPTIC</i> -3	Human	5'-ACCUGUUUGCGCUGUACAU dTdT-3'

**Table S2. Sequence of primers for quantitative real-time PCR analysis.**

Name	NCBI Gene ID	Species Specificity	Sequences of Primers
<i>ACTB</i>	60	Human	forward 5'- CCTTGACATGCCGGAG-3' reverse 5'-GCACAGAGCCTCGCCTT-3'

<i>CPTIC</i>	126129	Human	forward 5'-GGATGGCACTGAAGAGGAAA-3' reverse 5'-TCCTGGAAAAGGCATCTCTC-3'
<i>PDHA1</i>	5160	Human	forward 5'-TGGTAGCATCCCGTAATTTTGC-3' reverse 5'-ATTCGGCGTACAGTCTGCATC-3'
<i>PDHB</i>	5162	Human	forward 5'-AAGAGGCGCTTTCCTACTGGAC-3' reverse 5'-ACTAACCTTGTATGCCCCATCA-3'
<i>PDHX</i>	8050	Human	forward 5'-TTGGGAGGTTCCGACCTGT-3' reverse 5'-CAACCACTCGACTGTCACTTG-3'
<i>PC</i>	5091	Human	forward 5'-ACAGAGGTGAGATTGCCATCC-3' reverse 5'-CACTGCATCTACGTTGTTCTCC-3'
<i>PDP1</i>	54704	Human	forward 5'-TGTGAACTGAGCAGGATCTATGG-3' reverse 5'-GGAATGTACGATGAGGAACAACA-3'
<i>PKD1</i>	5163	Human	forward 5'-CTGTGATACGGATCAGAAACCG-3' reverse 5'-TCCACCAAACAATAAAGAGTGCT-3'
<i>ME1</i>	4199	Human	forward 5'-CTGCTGACACGGAACCCTC-3'

			reverse 5'-GATCTCCTGACTGTTGAAGGAAG-3'
<i>ME2</i>	4200	Human	forward 5'-ATGTTGTCCCGGTTAAGAGTAGT-3'
			reverse 5'-ACCAAGCATTGTCGTTCTTGT-3'
<i>ME3</i>	10873	Human	forward 5'-TGAAGAAGCGCGGATACGATG-3'
			reverse 5'-GAAAGCAGGGCGGGATTAGG-3'
<i>ACLY</i>	47	Human	forward 5'-ATCGGTTCAAGTATGCTCGGG-3'
			reverse 5'-GACCAAGTTTTCCACGACGTT-3'
<i>CD36</i>	948	Human	forward 5'-AAGCCAGGTATTGCAGTTCTTT-3'
			reverse 5'-GCATTTGCTGATGTCTAGCACA-3'
<i>FASN</i>	2194	Human	forward 5'-AAGGACCTGTCTAGGTTTGATGC-3'
			reverse 5'-TGGCTTCATAGGTGACTTCCA-3'
<i>SCD-1</i>	6319	Human	forward 5'-TTCCTACCTGCAAGTTCTACACC-3'
			reverse 5'-CCGAGCTTTGTAAGAGCGGT-3'

---

**Table S3. Related to Figures 2-3. Metabolite fragments used for GC/MS analysis.**

Metabolite	Carbons	Derivatization	m/z	Fragments for integration
$\alpha$ -Ketoglutarate	1,2,3,4,5	tBDMS	346	C <sub>14</sub> H <sub>28</sub> O <sub>5</sub> NSi <sub>2</sub>
Lactate	1,2,3	tBDMS	261	C <sub>11</sub> H <sub>25</sub> O <sub>3</sub> Si <sub>2</sub>
	2,3		233	C <sub>10</sub> H <sub>25</sub> O <sub>2</sub> Si <sub>2</sub>
Citrate	1,2,3,4,5,6	tBDMS	459	C <sub>20</sub> H <sub>39</sub> O <sub>6</sub> Si <sub>3</sub>
Fumarate	1,2,3,4	tBDMS	287	C <sub>12</sub> H <sub>23</sub> O <sub>4</sub> Si <sub>2</sub>
Malate	1,2,3,4	tBDMS	419	C <sub>18</sub> H <sub>39</sub> O <sub>5</sub> Si <sub>3</sub>
Norvaline	1,2,3,4,5	tBDMS	288	C <sub>13</sub> H <sub>30</sub> O <sub>2</sub> NSi <sub>2</sub>
Pyruvate	1,2,3	tBDMS	174	C <sub>6</sub> H <sub>12</sub> O <sub>3</sub> NSi
Succinate	1,2,3,4	tBDMS	289	C <sub>12</sub> H <sub>25</sub> O <sub>4</sub> Si <sub>2</sub>
Oleate	1-18	FAME	296	C <sub>19</sub> H <sub>36</sub> O <sub>2</sub>
Palmitate	1-16	FAME	270	C <sub>17</sub> H <sub>34</sub> O <sub>2</sub>
Stearate	1-18	FAME	298	C <sub>19</sub> H <sub>38</sub> O <sub>2</sub>